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Abstract
Metabolic syndrome (MS) may comprise several clinical conditions such as obesity, diabetes and inflammatory
disorders, which are characterized by metabolic imbalances. The study of glucose transport and regulation by
insulin in lymphocytes is important, since the way they increase inflammation and susceptibility to infections are
common in MS. We studied glucose internalization in isolated thymocytes and splenocytes, its regulation by
insulin, and the role of three glucose transporters (Gluts) in control and in MS rats. Control glucose internalization
and insulin responses were lower in splenocytes than in thymocytes. Control and insulin-induced glucose internali-
zation in thymocytes declined with age, while transport by splenocyte continued to respond to insulin. Control
thymocyte glucose internalization was blocked by antibodies against Glut 1 and 4, while the insulin response also
was blocked by an anti-Glut 3 antibody. On four month old control and insulin-induced response, splenocyte
transport was only blocked by Glut 1 and 4 antibodies. At six months splenocyte glucose internalization depended
on Glut 1 and was less sensitive to the effects of an anti-Glut 4 antibody. In MS splenocytes the capacity of anti-
Glut 1 antibodies to inhibit control and insulin-dependent glucose transport was less significant, and we found
that in MS rats, glucose internalization was dependent on Glut 3 and Glut 4. In summary, the altered metabolic
state present in MS rats shows signs of modulation of glucose internalization by the Glut1, Glut 3 and Glut 4 trans-
porters, compared with its own age control.
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Background
Metabolic Syndrome (MS) should be considered as a
cluster of mostly modifiable risk factors triggering a
proinflammatory state, that provide a higher risk of the
development of diabetes and cardiovascular diseases.
Specific cardiovascular disease risk factors might include
obesity, type 2 diabetes, hyperlipidemia, insulin resis-
tance and hypertension. Some other alterations, such as
a pro-coagulant state and pro-inflammatory signs, can
be included [1]. The characteristic of the MS is that its
clinical conditions share a metabolic imbalance, induce
an excessive release of inflammatory mediators and
have a marked stimulation of stress hormones and this,
in turn, has profound effects on energy and substrate
metabolism [2].
T h ei m m u n es y s t e mi sc r u c i al for the defense against
organisms that cause infections and against toxic products;
a single defect in any of its components can cause a break-
down in this defense system and lead to serious or fatal
diseases. The consequences can be systemic infections,
cancer, autoimmune disorders or metabolic impairments.
In diabetic patients the incorrect management of sepsis,
due to an inappropriate immune response, can cause
excess inflammation, which can also decrease longevity
[[3-5], and [6]].
Lymphocytes as part of the adaptive immune response
are critical for normal immune functions [7]. These cells
use glucose as a primary fuel source and a strict regula-
tion of glucose is required to maintain immune homeos-
tasis; they also divide rapidly and they have a high death
rate. They further have the ability to respond to the pre-
sence of pathogens, shifting from a quiescent phenotype
to a highly active state within hours of stimulation
[[5,6], and [8]]. During activation, lymphocytes must
dramatically alter their metabolism; they are able to
increase their oxidative phosphorylation enough to sup-
ply their need and must therefore increase the rate of
glycolysis. In this way many factors such as metabolic
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their glucose consumption [8]. The study of glucose
transport in lymphocytes and its regulation by insulin is
important in the MS, since the exacerbated immune
response participates in physiological and pathological
conditions of diabetes mellitus type II (T2DM), which is
an important component of this syndrome [9]. The rea-
son for the increased susceptibility of diabetic patients
to persistent infections is not fully understood, but it is
known that sepsis or infection, as in diabetic ulcers,
raises cytokine secretion, which exacerbates damage,
produces insulin resistance and diminishes lymphocyte
proliferation. Sepsis injury and lymphocyte response to
it can come from alterations in the intracellular calcium
homeostasis [10]. Some of the altered functions of dia-
betic lymphocytes can be restored by administration of
insulin [11] and a beneficial effect from this hormone
again depends on the calcium homeostasis. Other
changes such as reduced production of interleukins 2, 6
and 10 (IL-2, IL-6, and IL-10) are induced by raised
concentrations of glucose [12].
Glucose transport into the cell, its regulation and the
mechanism of action of the hormones involved, varies
among different tissues and organs as well as during
development [13,14]. Glucose transport also varies
according to the rate of division and to metabolic neces-
sities. Therefore differences in glucose transport between
immature and mature lymphocytes might be expected.
Glucose is transferred across the plasma membrane by
facilitated diffusion along a concentration gradient invol-
ving transport proteins called glucose transporters
(Gluts), which have been characterized according to their
transport properties and to the requirements of the tissue
in which they are expressed [15]. There are 14 isoforms,
which exhibit different specificities, kinetic properties
and tissue expression profiles. In lymphocytes, expression
of Glut 1, Glut 4 and Glut 3 molecules has been detected
[16-18]. To prevent death, lymphocytes over-express glu-
cose transporters, especially Glut 1, which is the major
glucose transporter in this type of cell [19,20].
Regulatory factors, such as insulin level and hypoxia
[21-23], enhance the expression of Glut1 transporters and
move Glut 4 transporter molecules from small tubulo-
vesicular elements near the endoplasmic reticulum into the
plasma membrane [24,25]. Also the calcium-calmodulin
complex may be a part of the intracellular signaling path-
way of this regulatory factor.
In this study, we used a rat model of MS developed in
our institution by Baños et al. [26]. The characteristics
of these rats are: moderate elevation of blood pressure,
hypertriglyceridemia, hyperinsulinemia, excessive visceral
adipose tissue, renal damage, high vascular reactivity,
high inflammatory state, but not hyperglycemia [27-30].
Due to the pro-inflammatory state and metabolic disor-
ders present in the MS, the aim of this study was to study
the glucose transport at two different stages of matura-
tion of the lymphocytes in these animals and the partici-
pation of three known glucose transporters in these types
of cells. Our interest increased due to the inflammatory
state and the non-diabetic condition of this model. We
studied the modulation of glucose transference in thymo-
cytes and splenocytes mediated by three different glucose
transporters (Glut 1, 3 and 4), using antibodies to block
glucose internalization, to possibly define the participa-
tion of the glucose transporters in the MS.
Methods
Animals
Control animals
Two control groups of male Wistar rats (Rattus norvegi-
cus) were studied; young 4 month old rats (150-200 g) and
medium age six month old rats (400-500 g). Control ani-
mals: 4 month old animals were used to measure the thy-
mus activity, which declines with age [31], and 6 months
old, because the MS model is fully achieved in rats at six
months of age. They were fed after weaning, with normal
rodent diet and water ad libitum. At the end of treatment
period, the rats were killed by decapitation to obtain the
blood, spleens and thymuses for experiments. Decapitation
was chosen to avoid the interference by any anesthetic and
to allow blood draining. Serum was obtained by blood
centrifugation.
Metabolic Syndrome animals (MS)
Male Wistar rats were fed from weaning (50-80 g) up to
six months of age, with normal rodent diet and a solu-
tion of 30% sucrose as the only liquid source. At the
end of the treatment these animals were medium age
adults (400-500 g), which were killed by the same proce-
dure as the other groups. To determine the MS, their
weight, blood glucose and triglyceride concentration,
blood pressure and insulin concentration were mea-
sured. These variables were also determined to the con-
trol animals.
Blood pressure measurements
Systolic arterial blood pressure was measured in conscious
animals using the tail-cuff method; the cuff was connected
to a pneumatic pulse transducer (Narco bio-systems Inc.,
Healthdyne Co.) and a programmed electro sphygmoman-
ometer. The mean was calculated. The recordings were
taken of six independent determinations by means of a
Grass polygraph (model 79, Grass Medical Instruments,
Quincy, MA).
Blood parameter determination
After overnight fasting (12 hours), the animals were
killed by decapitation and blood was collected. It was
spun and the serum was separated by centrifugation at
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stored at -70°C until needed.
Serum insulin Serum insulin was determined using a
commercial radioimmunoassay (RIA) kit specific for rat
(Linco Research, Inc. Missouri, USA); the sensitivity was
of 0.1 ng/mL and intra- and inter-assay coefficients of
variation were 5 and 10%, respectively.
Serum glucose Glucose concentration was assayed using
an enzymatic Kit SERA-PAK
R Plus (Bayer Corporation,
Sées, France).
Serum triglycerides Triglycerides (TGs) were deter-
mined by commercially available procedures (Randox,
Laboratories LTD, Antrim, United Kingdom).
Serum cholesterol Cholesterol was determined by com-
mercial enzymatic procedure SPINREACT cholesterol -LQ
(Spinreact S. A. Gerona Spain).
Homeostasis model assessment (HOMA) HOMA was
used as an index to measure the degree of insulin resistance
and was calculated by the formula: (insulin (μU/ml) ×
glucose (in mmol/L)/22.5) [32-34].
Cell Preparation
Immediately after blood draining, spleens and thymuses
were dissected and placed in cold Tyrode solution. All
solutions were bubbled with 95%O2-5%CO2,p O 2 160
and pCO2 21.3 mmHg. The organs were extracted from
the control and MS rats. Spleens and thymuses were cut
separately into small pieces (2 mm
2) and filtered through
fine gauze and then centrifuged 3 min at 1000 rpm. In
the spleen, erythrocytes were lysed by adding 3 ml of a
lysis solution to the pellet; (1 part of Tris (0.17 M) and 9
parts of NH4Cl (0.16 M)). The cells were gently agitated
in this buffer for 1 min and centrifuged again. They were
w a s h e dt w i c ew i t hT y r o d et or e m o v et h el y s i sb u f f e r .
Thymus cells were filtered and washed once and resus-
pended in Tyrode. Macrophages from both cell lines
were removed by incubating the cell at 37°C for 30 min
in plastic Petri dishes. The cells were then washed twice
in fresh Tyrode solution by centrifuging 3 min at
1000 rpm and resuspending the pellet. Cellular viability
was determined by the percentage of cells that excluded
0.3% Trypan Blue (Gibco-BRL) [35] in Tyrode in an
improved Neubauer haemocytometer 1/10 mm deep
(Clay-Adams, Parsippany, NJ, USA). The viability was of
76.5 ± 1.2%. There were no significant variations of cell
viability after the incubation period, so the changes
observed were due to the treatment and not to the varia-
bility in the cell population.
Glucose Transporter Protocol
Cells were centrifuged again and aliquots of 5 × 10
6 cells
(approximately 100 μl of the pellet) were placed in
Eppendorff tubes, centrifuged and the supernatant substi-
tuted by 100 μl of one of the following different solutions
added to each tube: 1) Tyrode solution (Tyr), 2) Tyrode
solution with 50 mU/L insulin (Insulin) (Eli Lilly),
approximately the postprandial dose reached in plasma,
3) Tyrode solution with 1 μM trifluoperazine (TPZ) (ICN
Biochemicals, Aurora OH, USA), a calcium-calmodulin
complex blocker [36,37]; 4) Tyrode containing commer-
cial anti-Glut1 antibodies (G1), directed against the
extracellular domain (1:1000), (Santa Cruz, Biotech),
raised in goat, 5) Tyrode containing commercial anti-
Glut 3 antibodies (G3), directed against the extracellular
domain (1:10,000), (Santa Cruz, Biotech), when used in
thymocytes and (1:5,000) when used in splenocytes, 6)
Tyrode containing commercial anti-Glut 4 antibodies
(G4), directed against the extracellular domain (1:10,000),
(Santa Cruz, Biotech), raised in goat, 7) Tyrode solution
plus an Affinipure goat anti-rabbit serum(serum), at the
same concentration as the antibodies used to block the
glucose transporters (negative control) (Jackson Immu-
noResearch Laboratories, West Grove, PA, USA), 8) Tyr-
ode solution with 0.1 μM cytochalasin B (Cyto) (Sigma,
St. Louis MO), a glucose transporter blocker (positive
control) [38]. All doses were chosen after obtaining a
dose-response curve in young and healthy animals. The
tubes were incubated for 1 h at 37°C with gentle agita-
tion. The cell suspensions were constantly shaken, and at
the end the suspensions were agitated again, so that glu-
cose concentration was homogeneous. After the incuba-
tion period the cells were centrifuged at 1000 rpm for
3 min. Glucose concentration in the initial solution and
in samples of the supernatant after 60 min of incubation
was measured by the glucose oxidase method.
Glucose Supernatant Determination
After the incubation time, 2 μl of the supernatants were
added to 200 μl of a glucose assay, (Diagnostic Chemi-
cals Limited, Oxford Co) to measure the glucose con-
centration by the glucose oxidase reaction [39], in a
Benchmark Plus microplate spectrophotometer (Bio-rad,
Hercules, CA) at 505 nm.
Ethics
All animals were lawfully acquired and the manipulation
of all animals in the research was carried out in accor-
dance with “The European Commmission Enviroment”
(Declaration of Helsinki): EC Directive 86/609/EEC for
animal experiments [40]. It also received the approval
from the Ethics Committee of the National Institute of
Cardiology. All reagents used were of the highest grade
available.
Statistical Analysis
Data were reported as micrograms of glucose subtracted
from the incubation media per gram of fresh tissue per
hour. Means and standard errors of at least 20 experiments
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ences on glucose internalization produced by the cell
populations. The Mann Whitney test was used to deter-
mine which differences were statistically significant consid-
ering p < 0.05 as significant. Student’stt e s tw a su s e dt o
compare control and insulin responses.
Results
Metabolic Syndrome Model
After six months of drinking a high sucrose solution the
animals develop many of the characteristics of the MS,
showing similar symptoms to the fructose-fed model
developed by Reaven [41]. The animals have moderately
elevated blood pressure, hypertriglyceridemia, hyperinsu-
linemia, central adiposity, insulin resistance, but not
hyperglycemia. Eventually, some of these animals
showed altered lymphocyte functionality manifested as
respiratory infections or abscesses. When this happened
the animals were discarded. We only used healthy speci-
mens. MS rats also have smaller surviving rates. Table 1
shows variables in these animals.
Insulin Effect on Glucose Internalization of Control and
MS Rat Lymphocytes
Thymocytes
Glucose internalization was significantly larger in imma-
ture thymocytes and they incorporated 3.31 ± 0.23 glu-
cose μg/fresh tissue g/h. There were differences between
4 and 6 months of age in control thymocytes, the 4
months old cells being higher glucose consumers. At
the stage of 4 months the value of glucose transport in
thymocytes was 51%; meanwhile at the age of 6 months
thymocytes decreased their glucose transport by 15%
(Figure 1A).
Insulin significantly increased glucose transport in thy-
mocytes at the age of 4 and 6 months old, but glucose
transport diminished with time; the insulin-induced
response at 6 months old was reduced to 66.4%.
Basal glucose internalizati o ni nt h y m o c y t e sf r o mM S
rats was the same as in 4 and 6 month old controls, but
they stopped responding to insulin (Figure 1A).
Splenocytes
In cells isolated from the spleen the glucose internaliza-
tion was not as high as in thymocytes. However this insu-
lin effect was more pronounced (19%) in immature
thymocytes than in splenocytes; these differences
decreased at the age of 6 months. Splenocytes incorpo-
rated 2.29 ± 0.12 glucose μg/fresh tissue g/h. and did not
change their transport through time. The insulin effect in
these cells was present at both ages (Figure 1A).
MS splenocytes decreased their glucose transport, but
they had a greater insulin-induced effect compared with
its own age control (Figure 1A).
Insulin effect on both cell populations was reduced by
ad o s eo f1μM of trifluoperazine, which is a calcium-
calmodulin inhibitor. Therefore calcium-calmodulin
could be one of the possible pathways of the insulin
effect. Trifluoperazine had no effect on control glucose
transport (Figure 1B).
Glucose Transporter Participation in Basal and Insulin-
induced Glucose Internalization of Young Rat
Lymphocytes
Thymocytes
At the age of 4 months, the participation of glucose
transport molecules in both basal and insulin-induced
glucose internalization was studied by incubating thymo-
cytes (immature cells) in the presence of commercial
anti-Glut1, anti-Glut 3 and anti-Glut4 antibodies. Anti-
bodies against the Glut1 and Glut4 molecules signifi-
cantly decreased basal and insulin-induced response.
Anti-Glut 3 antibodies had no effect on the basal trans-
port (Figure 2A). The higher insulin response of thymo-
cytes was blocked by antibodies against the Glut 1 and
Glut 4 transporters and also by antibodies against Glut 3
(Figure 2A).
Basal and insulin-induced glucose transport were
significantly decreased when thymocytes were incu-
bated with cytochalasin B. Control goat serum without
anti-glucose transporter antibodies did not alter either
basal or insulin-induced glucose internalization
(Figure 2B).
Table 1 Physiological variables measured on control and MS rats
4 MONTHS CONTROL 6 MONTHS CONTROL MS
Body weight (g) 250 ± 10.0 521.0 ± 6.2 530.0 ± 12.9
Intra-abdominal fat (g) 3.2 ± 0.8 4.3 ± 0.8 14.8 ± 4.0*
Blood Pressure (mmHg) 104 ± 2.0 110 ± 1.1 148 ± 2.9*
Total Cholesterol (mg/dl) 70.0 ± 1.6 74.7 ± 1.7 72.9 ± 2.4
Triglycerides (mg/dL) 51.6 ± 4.2 51.0 ± 5.8 109.6 ± 12*
Glucose (mmol/L) 5.76 ± 0.4 5.9 ± 0.3 5.38 ± 0.4
Insulin (μU/ml) 9.0 ± 2.8 6.5 ± 0.9 24.2 ± 5.7*
HOMA 1.5 ± 0.8 1.7 ± 0.5 5.2 ± 2.1*
Values are mean ± s.e.m. n = 20; *p < 0.01
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Glucose transporter molecule participation in both basal
and insulin-induced glucose internalization was also stu-
died in splenocytes (mature cells) in the same way as in
thymocytes and at the same age. Control and insulin-
induced glucose consumption by splenocytes was
blocked by anti-Glut 1 and anti-Glut 4 but not by anti-
Glut 3 antibodies (Figure 2A).
Basal and insulin-induced glucose internalization were
significantly decreased when splenocytes were incubated
with cytochalasin B. Control goat serum without anti-
glucose transporter antibodies did not alter basal or
insulin-induced glucose capture (Figure 2B).
Splenocyte Control and Insulin-induced Glucose
Internalization at Two Ages
Due to the fact that the stock of thymocytes is built up
in early life and the thymusf u n c t i o n sd e c l i n ea sa g e
advances, we decided to continue to study splenocytes
only. This decision was also made because the glucose
transport at 6 months old and in the MS thymocytes
declined and there was no response to insulin.
Different glucose transporter participation was observed
at the two ages in splenocytes control cells. Splenocytes
glucose internalization did not change through time, but
the way in which cells captured glucose was different. At
the age of 4 months, these cells incorporated glucose
through Glut 1 and Glut 4 and insulin response promoted
the entrance by the same transporters. At 6 months, Glut
1 also facilitated the entrance of glucose, but when the
cells were incubated with the antibody against Glut 4
(1:10,000) it no longer participated, although a tendency to
do so by insulin was observed. In the event, we concluded
that the transporters could be modified by age (Figure 3A).
Then the cells were incubated with a higher concen-
tration of anti Glut 4 antibodies (1:500) and a blockade
in both cases was observed (control and insulin). The
behavior of Glut 3 did not change with age (Figure 3B).
Figure 1 Insulin effect on glucose internalization of control and MS rat lymphocytes. A) Comparative glucose transport in control and MS
thymocytes and splenocytes, with and without insulin. B) Experiments with TPZ as a control of the possible pathway of the insulin effect. *p <
0.05 comparing the two types of cells;
♦p < 0.05 insulin effect when compared to control values incubated with Tyrode;
♥p < 0.05 comparing
between ages;
×p < 0.05 MS effect of the MS compared to its 6 months control; ⊕ p < 0.05 compared with its insulin control.
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Internalization with and without Insulin on the MS Model
Glucose transport in MS animals is lower compared
with control animals of the same age, but the response
to insulin is enhanced. In this model, it seems that Glut
1 does not mediate basal glucose intake, but when an
increase in the antibody concentration was used (1:500),
a blockade was observed, as well as in the insulin
response. This might suggest that in this condition the
splenocytes need more glucose transporter in the mem-
brane. Under control conditions, the participation of
Glut 4 in the MS cells is blocked, with the same con-
centration (1:500) of antibodies as previously used in the
6 month old animals. When the MS splenocytes were
stimulated by insulin at the same concentration of anti-
bodies against Glut 4, the blockade was complete. This
suggests that the quantity of antibody was sufficient to
block the response. An activation of Glut 3 in the basal
and insulin-induced transport was now observed in the
MS model (Figure 4).
Discussion
Lymphocytes, as part of the adaptive immune system, are
critical for normal immune functions [7]. They require
glucose as a primary fuel source and strict regulation of
glucose is required to maintain immune homeostasis.
Impairment of glucose transport in splenocytes and thy-
mocytes and its regulation by insulin is a common feature
of human diabetes, enhancing susceptibility to infections
[9]. Although the reason for increased susceptibility of dia-
betic patients to persistent infections is not fully under-
stood, the administration of insulin restores some of the
altered functions of diabetic lymphocytes [11]. Raised
concentrations of glucose also induce changes such as
Figure 2 Glucose transporter participation in basal and insulin-induced glucose internalization of young rat lymphocytes. A) Effect of
the three different antibodies against the glucose transporter on glucose transport of young (4 months) control cells and the insulin effect.
B) Experiments in the presence of an unspecific serum without antibodies against the glucose transporters and in the presence of cytochalasin B
(Cyto B), a non-selective glucose transporter blocker, * p < 0.05 comparing the two type of cells;
♦ p < 0.05 insulin effect when compared to
control values incubated with Tyrode; ▲ p < 0.05 compared to its own Tyrode control.
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studied and compared glucose transport and insulin effect
in immature thymocytes and mature splenocytes of con-
trol animals and MS animals.
In accordance with the observation that glucose trans-
port changes during development and maturation in many
cell types [13,14], we found that thymocytes show a very
important difference in their effect on glucose transport
when compared with splenocytes. This can be explained
by the fact that thymocytes are immature cells that might
be in the process of developing and therefore the meta-
bolic demand increases, due to the fact that these cells
initiate their activation, cell growth program and prolifera-
tion [42]. T cells exit the thymus and enter the peripheral
circulation as small quiescent cells (resting state), they
consume glucose at a low rate and consumption is limited
by the availability of trophic signals rather than by nutrient
availability [8]. These cells, due to their ability to respond
rapidly in the presence of pathogens or inflammatory
events, shift from a quiescent phenotype to a highly active
state within hours of stimulation. This result is similar to
the changes in glucose consumption in other blood cells
such as erythrocytes [14].
Glucose enters cells by facilitated diffusion [43] via
glucose transporter molecules [15].
Lymphocytes express Glut 1, Glut 3 and Glut 4 mole-
cules [16-18]. In this paper we observed that both basal
and insulin-induced glucose transport were inhibited by
cytochalasin B, a molecule that binds covalently and in a
reversible manner to all glucose transporters [38]. Anti-
Glut1 and anti-Glut4 antibodies blocked the insulin-
induced response, except in thymocytes, where Glut 3
participated in the insulin-induced response. These
results suggest the participation of other transporter
Figure 3 Splenocyte glucose transporter participation in basal and insulin-induced glucose internalization at two ages. A)C h a n g e so n
the effect of the three different antibodies, against the glucose transporter, on glucose transport at 4 and 6 months with and without insulin.
B) Given the different response to the anti Glut 4 antibodies there was the need to use a different antibody concentration (1:500);
◆p < 0.05 insulin
effect when compared to control values incubated with Tyrode; ▲p < 0.05 compared to its own control;
♥p < 0.05 comparison between ages.
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cytes. Glut proteins are highly regulated in physiological
as well as pathophysiological states. Levels of regulation
include gene transcription, protein expression and degra-
dation, cellular distribution, translocation and fusion and
also Glut activity [44].
Regulation of glucose transport is also modified during
development [13,14]. The capacity to respond to regula-
tory factors such as insulin has been studied in lympho-
cytes [8,45-47], but there are very few reports on
immature thymocytes [48]. In this paper we show that
incubation in the presence of insulin resulted in a signif-
icant increase in glucose capture both in splenocytes
and thymocytes.
Basal and insulin-induced glucose internalization by
thymocytes declines after some time and this can be due
to thymus atrophy. The stock of T lymphocytes is built
up in early life, so the function of the thymus is dimin-
ished in adults. In elderly adults it consists of fatty tissue.
H o w e v e r ,t h et h y m u ss t i l lf u n c t i o n sa sa ne n d o c r i n e
gland that stimulates the immune system and this phe-
nomenon is related to post-receptor defects in the
mechanism of insulin-mediated glucose uptake in target
tissues [31]. In the case of MS thymocytes there is a ten-
dency to reduced glucose transport and no response to
insulin. Age and obesity might explain the phenomenon,
as well as the glucose imbalance. Armoni et al [49] found
that Glut 4 stops being expressed in adipocytes with
aging and this can also happen in thymocytes. Armoni
also mentions that obesity is a factor that diminishes the
expression of Glut 4 in adipocytes and our MS animals
have a clear abdominal obesity.
Figure 4 Splenocyte glucose transporter participation in glucose internalization with and without insulin on the MS model. A) Changes
on the effect of the three different glucose transporter antibodies, on control and MS glucose transport are shown. Anti-Glut 3 antibodies
responded in the MS splenocytes only. B) Given the different response to the anti Glut 1 antibodies there was also the need to use a different
antibody concentration (1:500). Anti Glut 4 concentration used in the MS was the same (1:500) as in the previous experiments in control of six
months old animals.
◆ p < 0.05 insulin effect when compared to control values incubated with Tyrode; ▲ p < 0.05 compared with its own
control;
× p < 0.05 MS effect compared with its 6 months control.
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have never been exposed to antigens; they get activated
and migrate to lymphoid organs. This route is a very
high glucose-consuming process. In splenocytes a move-
ment of the glucose transporter 4 with aging is observed
and this can be explained by the fact that this transpor-
ter has a developmental expression. It has been reported
that this Glut is regulated, in a tissue-specific manner,
by a developmental program at early stages in different
tissues and this program may coordinate the expression
of other proteins of metabolic importance; therefore, it
should not be surprising that this change in expression
might also happen at later stages of development to
adjust to metabolic changes [50]. B cells also express
more Glut 4 with age and this might be due to the fact
that cells get more hypoxic as they get older. Hypoxia
has been reported as a Glut 4 expression promoter [21,
22, 51, and 52].
In the present paper we studied the participation of the
calcium-calmodulin complex in insulin increases in glu-
cose internalization through its inhibition, by using
trifluoperazine [36,53]. It has been reported that subse-
quent to the recognition of insulin at the cell surface,
intracellularly located glucose transporters are trans-
ported to the cell membrane, whereupon they increase
sugar uptake [54]. For these events to occur, the hor-
mone-receptor complex must release the signals that
induce incorporation of transporters into the plasma
membrane. Since transporter incorporation to the plasma
membrane is due to a vesicle fusion mechanism similar
to the exocytosis processes, calcium [54,55] and calmo-
dulin [37] have been proposed as doorways and regula-
tory agents. On the other hand, glucose and calmodulin
have also been found to regulate calcium uptake in insu-
linoma glucose-responsive cells [56]. Therefore, it would
be possible that trifluoperazine could block the increase
in glucose transport. When lymphocytes were incubated
simultaneously with insulin and trifluoperazine, the
increase in glucose internalization induced by insulin was
decreased. These results indirectly support the role of
Ca
2+ and calmodulin as the intracellular messenger of
the insulin receptor complex, since calmodulin must
interact with Ca
2+ to induce vesicle fusion to the plasma
membrane. It has also been previously reported that an
increase in intracellular calcium level leads to increases
in cellular proliferation and secretion of intracellular pro-
ducts [55].
MS is associated with abdominal obesity, blood lipid
disorders, inflammation, insulin resistance and an
increased risk of cardiovascular diseases. Our model
concedes with many of the MS characteristics and the
obesity that these animals develop may be a risk factor
for deteriorating cellular immune function [57].
The fact that the MS cells decrease their glucose
transport compared to control cells might be due to the
phenomenon called immunosenescence, which covers
numerous immune system changes with age [58]. The
MS accelerates aging. In the MS model an activation of
Glut 3 transporter in basal transport is present. The
insulin-stimulated response in the MS animals persists
and a movement of the glucose transporter 1 and an
activation of the glucose transport 3 by the effect of
insulin can also be observed. These rats have hyperinsu-
linemia and it has been reported that in muscle cells
chronic insulin stimulation can activate the over expres-
sion of Glut 1 and Glut 3 by two different pathways
[59]. Szablewski described that Glut 1 in diabetic
patients is over expressed in lymphocytes [60]. Although
our animals are not diabetic they have a metabolic
disturbance.
We postulate that, in our model, there are glucose
transporter movements due to the metabolic disorders
that these animals suffer [26-29]. Fu et al [16] proposed
that high Glut 1 and 3 expressions could provide cellu-
lar fuel for the immune response. They also proposed
that high affinity to Glut 3 in other immune cells might
allow cells to compete with pathogens for hexoses. The
participation of glucose transporters 1 and 3 suggests
that splenocytes have an increased metabolic need for
glucose because they have a sustained immune response
due to the MS state or, possibly, because another cell
population is activated. The possible decrement in the
expression of Glut 4 after insulin stimulation, in this
model, can also coincide with the fact that Glut 4
decrease, with age and the metabolic process that these
rats are going through, can be compared with an accel-
erated aging process. Besides, Cartee [61] found that
Glut 4 protein decreases with age in cardiomyocytes, so
this could be also true for the splenocytes.
Conclusions
We conclude that in rat, thymocytes consume more glu-
cose than splenocytes and respond better to regulatory
factors such as insulin when they are at an active stage.
Lymphocytes show three different glucose transporters:
Glut1, Glut 3 and Glut4. Thymocytes use Glut 1 and Glut
4 for basal glucose consumption and the three transpor-
ters participate in the insulin-induced response. Mean-
while, in splenocytes, glucose transport is made by Glut 1
and Glut 4 in basal and in the MS the glucose transport is
diminished and the three glucose transporters are acti-
vated. There is a regulation of the transporters, where
Glut 1 raises its participation, Glut 3 is activated and Glut
4 diminishes its response in the insulin stimulation. The
participation of the calcium-calmodulin complex, as a pos-
sible intracellular signaling pathway for insulin, could
Carbó and Guarner Diabetology & Metabolic Syndrome 2010, 2:64
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Page 9 of 11suggest part of the regulation of this hormone in the
incorporation of glucose into the cell and in the glycemic
control of these animals. These results could contribute to
a better understanding of why in the MS the immune sys-
tem is constantly activated to respond to persistent infec-
tions, through the regulation of glucose transport.
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